It was quite a busy and eventful day for the company.
The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden.
Shares of Bausch Health, Inc. BHC gained 14.7% in a week on reports of refinancing its debt to enable the impending sale of its eye care company, Bausch + Lomb BLCO. The industry declined 0.6% during this...
The highly indebted healthcare stock rose on rumors it may be selling itself.
Bausch Health Companies had the 8th-highest Vol/OI ratio in Wednesday trading. The pharmaceutical company’s unusual options activity suggests it might have more gains ahead.
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END
/PRNewswire/ -- The Global Dry Eye Syndrome market has been growing substantially in the past years and is expected to continue through 2030. Dry Eye Syndrome...
Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better,...